The MEG business of Elekta has been acquired by York Instruments Ltd
We advised Elekta AB on the sale of MEGIN, its MEG business, to York Instruments Ltd. Financial details have not been disclosed.
Magnetoencephalography (MEG) is the brain activity-mapping business of Elekta. MEG is a diagnostic functional neuroimaging technique for mapping brain activity. This can be applied in a clinical setting to find locations of abnormalities as well as in a research setting to simply measure brain activity. Elekta's MEG business, known as MEGIN, is a leading supplier of magnetoencephalography (MEG) technology, with more than 100 delivered MEG systems worldwide.
York Instruments Ltd. is a company specializing in magnetic measurements and their healthcare applications. Using the very latest technologies and methodologies, York Instruments is focused on magnetoencephalography (MEG) and its ability to effectively assess neural networks. York Instruments' revolutionary MEG technology allows for earlier and improved diagnostic capability in relation to a variety of neurological diseases and conditions.
Elekta AB is a Swedish company that provides radiation therapy, radiosurgery, related equipment and clinical management for the treatment of cancer and brain disorders. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.
Oaklins' team in Finland acted as financial advisor to the seller in this transaction. Oaklins' Dutch team supported the transaction by initially approaching Elekta AB.
Talk to the deal team
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.Learn more
Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.Learn more